E2

E2 Biopharma is a clinical-stage biotechnology company focused on developing novel small molecule therapeutics for neurological and psychiatric disorders. The company's lead program, E2-001, is a selective modulator of the metabotropic glutamate receptor 5 (mGluR5) being investigated for the treatment of Fragile X syndrome and other neurodevelopmental conditions. By targeting specific neurotransmitter pathways, E2 Biopharma aims to address the underlying pathophysiology of complex brain disorders that currently have limited treatment options. The company leverages deep expertise in neuroscience and medicinal chemistry to advance its pipeline through clinical development.